The Efficacy and Safety of Once-daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-daily Budesonide/Formoterol in a Subgroup of Patients from China with Symptomatic COPD at Risk of Exacerbations (FULFIL Trial)

Author:

Zheng Jinping1,Zhong Nanshan1,Wang Changzheng2,Huang Yijiang3,Chen Ping4,Wang Limin5,Hui Fuxin6,Zhao Li7,Wang Haoyan8,Luo Linda9,Du Xin10,Han Goh Aik9,Lipson David A.1112

Affiliation:

1. State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong, China;

2. Department of Respiratory Medicine, Xinqiao Hospital, Third Military Medical University, Chongqing, China;

3. Department of Respiratory Medicine, Hai Nan Provincial People’s Hospital, Haikou, Hainan, China;

4. Department of Respiratory Medicine, General Hospital of Shenyang Military Command, Shenyang, Liaoning, China;

5. Respiratory Department, Hangzhou First People’s Hospital, Hangzhou, Zhejiang, China;

6. Respiratory Department, Wuxi People’s Hospital, Wuxi, Jiangsu, China;

7. Department of Respiratory Medicine, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China;

8. Department of Respiratory Medicine, Beijing Friendship Hospital, Capital Medical University, Beijing, China;

9. GSK, Shanghai, China;

10. GSK, Beijing, China;

11. GSK, King of Prussia, PA, USA;

12. Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

Funder

GSK

Publisher

Informa UK Limited

Subject

Pulmonary and Respiratory Medicine

Reference14 articles.

1. Global Initiative for Chronic Obstructive Lung Disease. GOLD 2017 Global strategy for the diagnosis, management and prevention of COPD. Available from: http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/.

2. Prevalence of Chronic Obstructive Pulmonary Disease in China

3. Triple Therapy of Umeclidinium + Inhaled Corticosteroids/Long-Acting Beta2 Agonists for Patients with COPD: Pooled Results of Randomized Placebo-Controlled Trials

4. FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3